RomânăFără categorie
Genetic Mutations in Lung Cancer and Other Cancers — Complete Guide for Patients: From EGFR and KRAS to ALK, RET, and BRAF
Have you been diagnosed with lung cancer and your doctor has recommended a molecular genetic panel? Or does your biopsy report mention terms like “EGFR mutant,” “KRAS G12C,” “ALK positive,” or “PD-L1 70%” and you’re not sure what they mean for your treatment? You’ve come to the right place. This guide explains, in an easy-to-understand manner, the most important mutations identified in lung cancer and other cancers — and especially what specific therapies unlock each mutation.
Why tumor genetic testing has revolutionized modern oncology
Until 15 years ago, lung cancer was treated almost exclusively with chemotherapy — the same regimen for all patients, regardless of tumor biology. Today we know that lung cancer is not a single disease , but dozens of distinct molecular diseases, each with its own “genetic engine” that makes it grow and spread.
Identifying this genetic driver — through IHC, PCR, or NGS (next-generation sequencing) testing — allows the oncologist to choose the right targeted therapy , which specifically attacks cancer cells without destroying healthy cells to the same extent as classic chemotherapy.
According to the National Cancer Control and Prevention Plan (PNCC) in Romania, molecular genetic testing is fully reimbursed for patients with NSCLC, colorectal, ovarian, breast and other types of lung cancer — upon the recommendation of an oncologist.
NSCLC Lung Cancer — Actionable Mutation Map
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer (~85% of cases). In patients with lung adenocarcinoma (non-squamous), a full panel of biomarkers is mandatory , as over 60% of them have at least one mutation for which there is an approved targeted therapy.
1. EGFR Mutations — The Most Common “Driver” of Lung Adenocarcinoma
What is EGFR?
EGFR (Epidermal Growth Factor Receptor) is a cell surface protein that, when mutated, continuously sends signals for uncontrolled cell proliferation.
- Frequency: 10–15% in Western populations; 40–50% in East Asian populations
- Classic mutations: Exon 19 deletion (45% of cases) and L858R exon 21 mutation (45%)
- Rare mutations: G719X, L861Q (~5–8%)
- Resistance mutations: T790M (occurs after treatment with I-II generation TKIs), C797S
What therapies does it open?
Classic EGFR mutations respond well to tyrosine kinase inhibitors (TKIs) — oral pills taken daily:
| Generation | Drug | Indication |
| Generation I | Erlotinib, Gefitinib | Classic EGFR mutations |
| Generation II | Afatinib, Dacomitinib | Classic mutations + some resistances |
| Generation III | Osimertinib (Tagrisso) | Gold standard 2025; also covers the T790M mutation |
Osimertinib is the preferred first-line treatment according to the NCCN and ESMO 2025 guidelines — with a response rate of 80–85% and a median progression-free survival of 18–20 months.
💊 Key therapeutic implication: If your tumor has mutated EGFR, classic chemotherapy is not the first choice . Oral osimertinib treatment replaces infusions in the first line.
2. KRAS G12C Mutation — From “Impossible Target” to Revolutionary Therapy
Why was KRAS special?
KRAS was considered “untargetable” for 40 years — its protein structure did not provide a binding site for drugs. The discovery of the specific G12C mutation site changed everything in 2021.
- Frequency in NSCLC: ~13% of adenocarcinomas
- Frequency in colorectal cancer: 40–50% (all KRAS mutations)
- Frequency in pancreatic cancer: ~90%
What therapies are available in 2025?
- Sotorasib (Lumakras) — first FDA-approved KRAS G12C inhibitor; 960 mg/day orally
- Adagrasib (MRTX849) — 600 mg twice/day; response rate 42%, PFS 8.5 months
💡 New 2025: Combining sotorasib or adagrasib with chemotherapy (platinum-pemetrexed) significantly improves survival compared to monotherapy — estimated PFS 10–12 months. KRYSTAL clinical trials are ongoing.
Non-G12C KRAS mutations (G12D, G12V, G12A, etc.) — which represent the majority of KRAS mutations — do not yet have approved therapies and are managed with chemotherapy ± PD-L1-based immunotherapy.
3. ALK, ROS1, NTRK, and RET Fusions — The “Happy Fusions” of Lung Oncology
Gene fusions occur when two distinct genes accidentally “stick together”, creating a hybrid protein that stimulates tumor growth. They are called “happy” because they respond spectacularly to targeted therapies .
ALK (Anaplastic Lymphoma Kinase)
- Frequency in NSCLC: 3–7%; more common in young nonsmokers
- Therapies: Alectinib (preferred first line), Lorlatinib (generation III, active also at the brain level), Brigatinib
- PFS with alectinib: 34.8 months — a remarkable result compared to classic chemotherapy
ROS1
- Frequency: 1–2% of NSCLC
- Therapies: Crizotinib (first line), Lorlatinib (second line), Entrectinib
NTRK 1, 2, 3 (Mergers)
- Frequency: Rare in NSCLC, but present in multiple cancer types
- Therapies: Larotrectinib, Entrectinib — approved agnostic to tumor type (works regardless of organ of origin)
RET (mergers)
- Frequency in NSCLC: 1–2%
- Therapies: Selpercatinib (Retevmo), Pralsetinib — FDA/EMA approved
⚠️ Important: If your report says “ALK fusion positive” or “RET fusion positive,” do not accept chemotherapy as your first option without discussing with your oncologist about available targeted therapy.
4. BRAF V600E Mutation — Link to Melanoma and Lung Cancer
BRAF V600E is a well-known mutation in melanoma, but it also occurs in NSCLC (~2–3%).
- Therapies in NSCLC with BRAF V600E: Dabrafenib + trametinib combination (BRAF inhibitor + MEK inhibitor) — also approved in lung cancer
- Response rate: ~64%; PFS ~10 months
The same combination works in melanoma, thyroid cancer, and colorectal cancer with BRAF V600E — an example of tumor type-agnostic therapy .
5. PD-L1 — The Key to Modern Immunotherapy
PD-L1 (Programmed Death Ligand 1) is not a mutation, but a cell surface protein that “hides” the tumor from the immune system. The level of PD-L1 expression (expressed as a percentage by the TPS or CPS score) determines eligibility for immunotherapy.
| PD-L1 TPS score | Therapeutic indication |
| ≥ 50% | Pembrolizumab monotherapy (first line, without chemotherapy) |
| 1–49% | Pembrolizumab + chemotherapy (platinum doublet) |
| < 1% | Chemotherapy ± bevacizumab; immunotherapy less effective |
💊 New 2025: The combination of pembrolizumab with osimertinib in EGFR-mutant patients with elevated PD-L1 is in advanced clinical evaluation — FDA/EMA approval anticipated in 2025–2026.
6. STK11/LKB1 Mutations — Why Immunotherapy Can Fail
STK11 (LKB1) is a tumor suppressor gene that, when mutated, creates a tumor microenvironment resistant to immunotherapy . Patients with STK11 mutations in NSCLC have significantly lower response rates to pembrolizumab than those without this mutation.
Direct therapeutic implication: If you have NSCLC with mutated STK11 and elevated PD-L1, your doctor may prefer chemotherapy as a first-line treatment over immunotherapy alone — a counterintuitive decision but supported by clinical data.
Emerging Therapies 2025: SHP2 inhibitors and AMPK activators are in clinical trials for STK11 mutant NSCLC.
7. Same mutations, different cancers — The concept of tumor type agnostic therapy
A revolutionary concept in oncology 2024–2025 is that the mutation matters more than the organ of origin . The FDA has approved several “tumor-agnostic” therapies — they work regardless of the type of cancer, if the mutation is present:
| Mutation / Biomarker | Associated cancer(s) | Approved tumor-agnostic therapy |
| MSI-H / dMMR | Colorectal, endometrial, gastric, pulmonary | Pembrolizumab |
| NTRK mergers | Pulmonary, breast, colorectal, thyroid, sarcomas | Larotrectinib, Entrectinib |
| TMB ≥ 10 mut/Mb | Any type of solid tumor | Pembrolizumab |
| BRAF V600E | Melanoma, lung, colorectal, thyroid | Dabrafenib + Trametinib |
| HER2 (ERBB2) amplified | Breast, gastric, pulmonary, colorectal | Trastuzumab deruxtecan (T-DXd) |
What tests are billed in Romania in 2025?
According to the National Oncology Program (PNCC), for NSCLC lung cancer the following are fully reimbursed:
- Metastatic/locally advanced non-squamous NSCLC: Full NGS panel — EGFR, BRAF V600E, KRAS G12C, ALK, ROS-1, NTRK, RET, PD-L1
- Squamous NSCLC (smokers): PD-L1
- NSCLC in operable stages: EGFR, ALK, PD-L1
📋 Your right as a patient: If you have been diagnosed with lung adenocarcinoma and have not received a recommendation for complete molecular testing, you have the right to ask your oncologist for a report for an NGS panel reimbursed by PNCC .
🧬 Genetic Mutations in Cancer — Complete Explanatory Tables for Patients
📊 TABLE 1 — What each mutation is and what cancer it occurs in (in simple terms)
| mutation | What is it, in simple terms | Cancers in which it occurs frequently | How frequent is it? |
| EGFR | The “engine” that continuously sends signals for uncontrolled cell growth. Like a stuck accelerator pedal. | Lung (NSCLC), colorectal, head and neck cancer | 10–15% of Western NSCLC; 40–50% in Asians |
| KRAS G12C | A specific variant of the KRAS gene — for 40 years considered “untreatable.” Now there are targeted drugs. | Lung cancer (NSCLC), colorectal, pancreatic | ~13% of lung adenocarcinomas; 40–50% colorectal |
| KRAS non-G12C | Other KRAS variants (G12D, G12V, G12A, etc.) — common but no approved targeted therapies yet | Pancreatic cancer (90%!), colorectal (40–50%), lung | The most common mutation in cancer in general |
| ALK (fusion) | Two genes that “stick” together incorrectly and create a hybrid protein that accelerates tumor growth | Lung cancer (NSCLC) — especially in young non-smokers | 3–7% of NSCLC |
| ROS1 (fusion) | Similar to ALK — an accidental gene “splicing” | Lung cancer (NSCLC) | 1–2% of NSCLC |
| RET (merger) | Another genetic fusion — responds excellently to specific drugs | Lung cancer, medullary thyroid cancer | 1–2% of NSCLC |
| NTRK 1/2/3 (fusion) | Rare fusions, but with approved therapies regardless of cancer type | Pulmonary, breast, colorectal, thyroid, sarcomas | Rare (1–3%), but present in many types of cancer |
| BRAF V600E | A point mutation that activates a signaling pathway (MAPK). Well-known from melanoma. | Lung cancer (2–3%), melanoma, thyroid, colorectal | 2–3% NSCLC; 50% melanoma |
| PIK3CA | Activates the PI3K/AKT signaling pathway — the “fuel” of cell growth | Breast (HR+/HER2−), colorectal, endometrial, ovarian cancer | 15–20% of solid tumors |
| HER2 (ERBB2) | Overexpressed or mutated cell surface protein — accelerates cell multiplication | Breast, gastric, lung, colorectal cancer | 15–20% breast cancer; 10–15% gastric |
| TP53 | The “genome guardian” gene — when it breaks down, cells no longer die normally | Over 50% of ALL cancers | The most common mutation in cancer |
| PTEN | Tumor suppressor gene — the cell’s safety brake. When it is lost, cells multiply uncontrollably. | Endometrial (30–40%), prostate (30%), breast (10–20%), glioblastoma | 10–20% of cancers |
| STK11/LKB1 | A suppressor gene that regulates cellular metabolism and immune response. The mutation makes the tumor “resistant” to immunotherapy. | Lung cancer (NSCLC) | 15–20% of NSCLC |
| MSI-H / dMMR | The DNA “error correction” system is defective — the tumor has many mutations and is visible to the immune system | Colorectal (15%), endometrial (20–40%), gastric, pulmonary | Variable — 15% colorectal |
| PD-L1 | It is NOT a mutation, but a protein through which the tumor “hides” from the immune system | Pulmonary, cervical, gastric, bladder, triple-negative breast | Present in varying degrees in all cancers |
| TMB (Tumor Mutational Burden) | The total number of mutations in the tumor. The higher the number, the more visible it is to the immune system. | All types of cancer (assessed by NGS) | ≥ 10 mut/Mb = increased TMB |
📊 TABLE 2 — Which test detects each mutation and how to collect the sample
| Mutation / Biomarker | Sample type | Test method | PNCC Romania settled? | Who can request the test? |
| EGFR (exons 18–21) | Tumor tissue (paraffin block) or plasma (blood) | NGS, PCR, IHC | ✅ YES — Metastatic/locally advanced non-squamous NSCLC | Oncologist, pulmonologist, thoracic surgeon |
| EGFR T790M (resistance) | Plasma (EDTA blood) | PCR/NGS | ✅ YES — for resistance monitoring | Oncologist |
| KRAS G12C | Tumor tissue | NGS | ✅ YES — included in the NSCLC and colorectal panel | Oncologist |
| KRAS/NRAS (all mutations) | Tumor tissue | PCR/NGS | ✅ YES — for colorectal cancer mandatory | Oncologist, gastroenterologist, surgeon |
| ALK (fusion) | Tumor tissue | NGS + IHC (confirmation) | ✅ YES — NSCLC | Oncologist, pulmonologist |
| ROS-1 (fusion) | Tumor tissue | NGS + IHC | ✅ YES — NSCLC | Oncologist |
| RET (merger) | Tumor tissue | NGS | ✅ YES — included in the NSCLC panel | Oncologist |
| NTRK 1/2/3 (fusions) | Tumor tissue | IHC (screening) + PCR/FISH/NGS (confirmation) | ✅ YES — colorectal, s â n, NSCLC | Oncologist |
| BRAF V600E | Tumor tissue | NGS/PCR | ✅ YES — NSCLC and colorectal | Oncologist |
| BRCA1/2 (somatic — tumoral) | Tumor tissue (paraffin block) | NGS | ✅ YES — high grade ovarian stage III – IV ; HER2 − advanced | Oncologist |
| BRCA1/2 (germline — hereditary) | Blood or saliva | NGS + MLPA | ✅ YES — ovarian cyst ( specific criteria) | Oncologist |
| HRD-GIS (DNA repair deficiency) | Tumor tissue | NGS | ✅ YES — ovarian BRCA-negative | Oncologist / pathologist |
| MSI/dMMR | Tumor tissue | IHC (4 proteins: MLH1, MSH2, MSH6, PMS2) | ✅ YES — colorectal (mandatory), endometrial | Oncologist |
| PD-L1 | Tumor tissue | IHC | ✅ YES — NSCLC, gastric, esophageal, cervical, urothelial | Oncologist, pulmonologist, gastroenterologist |
| HER2 (IHC) | Tumor tissue | IHC | ✅ YES — s â n, gastric, esophageal | Oncologist, surgeon |
| HER2 (SISH/FISH) | Tumor tissue | FISH / SISH | ✅ YES — if IHC shows HER2 2+ | Anatomical pathologist (automatic) |
| PIK3CA (hotspot mutations) | Tumor tissue or blood | NGS/PCR | ✅ YES — included in colorectal cancer panels | Oncologist |
| HR (ER/PR) + Ki-67 | Tumor tissue | IHC | ✅ YES — breast cancer ( all patients ) | Oncologist, gynecologist, surgeon |
| TMB (mutational burden) | Tumor tissue | NGS (comprehensive panel) | ⚠️ Partially included in NGS panels | Oncologist |
| ctDNA (liquid biopsy) | Blood (EDTA plasma) | Ultrasensitive NGS | ⚠️ Not standard in PNCC 2025; available privately | Oncologist |
📊 TABLE 3 — What targeted therapy opens each mutation (simplified therapeutic guide)
| The identified mutation | What does it mean for treatment? | Available medicines (2025) | Administration form |
| EGFR exon 19 deletion or L858R | ✅ You no longer receive chemotherapy as a first choice — there are specific pills | Osimertinib (Tagrisso) — gold standard; Gefitinib, Erlotinib (generation I); Afatinib, Dacomitinib (generation II) | Daily oral pill |
| EGFR T790M (occurs in resistance) | ✅ Osimertinib covers and this resistance — no urgent change needed | Osimertinib (Tagrisso) generation III | Daily oral pill |
| EGFR exon 20 insertions | ⚠️ Not responding to standard TKI — there is a specific bispecific antibody | Amivantamab (Rybrevant) | Intravenous infusion |
| KRAS G12C | ✅ First ” curable ” KRAS mutation through targeted therapy | Sotorasib (Lumakras) 960 mg/day; Adagrasib (MRTX849) 600 mg x2/day | Daily oral pill |
| Non-G12C KRAS (G12D, G12V, etc.) | ⚠️ There is no specific approved therapy — chemotherapy + PD-L1-targeted immunotherapy | Pembrolizumab if PD-L1 ≥ 50%; Platinum chemotherapy | Infusion + pills |
| ALK positive (fusion) | ✅ Spectacular response to ALK inhibitors — NOT chemotherapy as first choice | Alectinib (first-line preferred); Lorlatinib (active and cerebral); Brigatinib | Daily oral pill |
| ROS1 positive (fusion) | ✅ Targeted therapy available | Crizotinib , Lorlatinib, Entrectinib | Daily oral pill |
| RET (fusion) | ✅ FDA/EMA approved therapy | Selpercatinib (Retevmo) , Pralsetinib | Daily oral pill |
| NTRK 1/2/3 positive (fusion) | ✅ Tumor type agnostic therapy — functions regardless of the organ | Larotrectinib , Entrectinib | Daily oral pill |
| BRAF V600E | ✅ Combination of two specific pills — approved and in lung cancer | Dabrafenib + Trametinib (mandatory combination) | 2 daily oral pills |
| PIK3CA (HR+/HER2− breast) | ✅ Add a specific pill to your hormone treatment | Alpelisib (Piqray) + Fulvestrant (or aromatase inhibitor) | Daily pill + monthly injection |
| HER2 overexpressed (IHC 3+) | ✅ Monoclonal antibodies or antibody-drug conjugates | Trastuzumab (Herceptin) + Pertuzumab; T-DM1 (Kadcyla); Trastuzumab deruxtecan (Enhertu) | Intravenous infusion |
| HER2-low (IHC 1+ or 2+/FISH neg) | ✅ New 2025: now eligible for HER2 treatment (new category ! ) | Trastuzumab deruxtecan (T-DXd / Enhertu) | Intravenous infusion |
| BRCA1/2 mutant (ovarian, breast, prostate, pancreatic) | ✅ Special pills that ” exploit” the DNA repair defect | Olaparib (Lynparza) , Niraparib, Rucaparib | Daily oral pill |
| MSI-H / dMMR | ✅ Immunotherapy — the immune system sees the tumor and attacks it | Pembrolizumab (Keytruda) ± Lenvatinib; Dostarlimab | Infusion every 3–6 weeks |
| PD-L1 ≥ 50% (pulmonary) | ✅ Immunotherapy without chemotherapy in the first line | Pembrolizumab (Keytruda) monotherapy | Infusion every 3 weeks |
| PD-L1 1–49% (pulmonary) | ✅ Immunotherapy + chemotherapy in combination | Pembrolizumab + platinum doublet | Infusion + chemotherapy |
| PD-L1 < 1% (pulmonary) | ⚠️ Immunotherapy less effective alone — chemotherapy ± bevacizumab | Carboplatin + pemetrexed ± bevacizumab | Intravenous infusion |
| STK11 mutant + PD-L1 elevated | ⚠️ ATTENTION : even if PD-L1 is elevated, immunotherapy alone works less — chemotherapy is the preferred treatment ! | Platinum chemotherapy; SHP2 inhibitors (clinical studies) | Intravenous infusion |
| TMB ≥ 10 mut/Mb | ✅ Immunotherapy regardless of tumor type (approved tumor-agnostic) | Pembrolizumab regardless of organ | Infusion every 3 weeks |
📊 TABLE 4 — How to interpret treatment response through molecular markers
| Clinical situation | What is being monitored? | Good sign | Alarm sign — what the doctor does |
| Under TKI (osimertinib, alectinib, etc.) | Chest CT at 8–12 weeks; ctDNA (optional) | The tumor is shrinking or stable | Tumor growth → repeat biopsy or ctDNA for resistance mutation |
| EGFR T790M appeared in follow-up | ctDNA from blood (plasma) | — | T790M detected → osimertinib already covers this → continue or add chemotherapy |
| Sub KRAS G12C inhibitor (sotorasib/adagrasib) | CT every 8 weeks; LFT monthly | Partial or complete response (37–42% of patients) | Progression → chemotherapy is added or the regimen is changed |
| Under pembrolizumab (immunotherapy) | CT at 9–12 weeks; sometimes pseudo-progression (tumor appears larger before shrinking) | Stable or shrinking tumor; normal inflammatory markers | Definite progression confirmed at 2 consecutive CT scans → change of treatment |
| Under alpelisib (PIK3CA inhibitor) | Blood glucose weekly for the first 4 weeks, then monthly | Blood glucose < 160 mg/dL; stable or shrinking tumor | Blood glucose > 250 mg/dL → dose reduction + metformin ; Severe skin rash → treatment break |
| Under trastuzumab (HER2 positive) | Echocardiography (LVEF) at 3 months; tumor markers CA 15-3 | LVEF > 50% maintained; CA 15-3 decreasing | Low LVEF → trastuzumab pause + cardiological consultation |
| Under PARP inhibitors (olaparib, niraparib) | Monthly blood count; creatinine | Hemoglobin > 8 g/dL; platelets > 75,000 | Severe anemia → dose reduction or transfusion; Thrombocytopenia → treatment interruption |
📊 TABLE 5 — Common side effects of targeted therapies and how to prepare
| drug | Common side effects | When to call the doctor urgently | What you can do at home |
| Osimertinib (Tagrisso) | Rash (70%), diarrhea (58%), fatigue | Difficulty breathing or new dry cough → pneumonitis ( stop the medication immediately!) | Daily moisturizer; avoid direct sun; SPF 50+ sun protection |
| Alectinib / Lorlatinib (ALK inhibitors) | Constipation, edema, weight gain (lorlatinib: neuropsychiatric effects) | Double vision, confusion, severe mood swings | High-fiber diet; weekly weight monitoring |
| Sotorasib / Adagrasib (KRAS G12C) | Diarrhea (33–40%), nausea, fatigue, hepatotoxicity | Diarrhea > 4 stools/day or with blood; jaundice (yellowing of the eyes/skin) | Loperamide at first signs of diarrhea; avoid alcohol; monthly liver tests |
| Alpelisib (Piqray) (PIK3CA) | Hyperglycemia (high blood sugar), rash, diarrhea, fatigue | Blood glucose > 250 mg/dL; extensive rash (>30% body surface area) | Mandatory low-sodium/low-glucose diet; preventive metformin; avoid sugary juices completely |
| Pembrolizumab (immunotherapy) | Fatigue, rash, diarrhea, endocrinopathy (thyroid) | Acute respiratory distress, severe joint pain, confusion → severe immunological toxicity | TSH + cortisol every 3 months; do not take anti-inflammatories without a doctor’s advice |
| Trastuzumab (Herceptin) | Infusion reactions (chills, fever), cardiomyotoxicity | on exertion → urgent cardiac ultrasound | Notify your doctor if you have a cold before your infusion; don’t miss scheduled echocardiograms |
| Olaparib / Niraparib (PARP inhibitors) | Anemia, fatigue, nausea, thrombocytopenia | Hemoglobin < 8 g / dL → extreme weakness ; spontaneous bruising → thrombocytopenia | Iron-rich diet; rest; mandatory monthly blood count |
| Dabrafenib + Trametinib (BRAF+MEK) | Fever (very common 50–70%), rash, photosensitivity | Fever > 38.5°C persistent > 24h → possible hospitalization | Paracetamol for fever; avoid the sun; total sun protection; abundant hydration |
📊 TABLE 6 — Treatment resistance: what it means and what comes next
| Initial treatment | Sign that resistance has emerged | What new mutation can occur? | What does the doctor do? |
| Osimertinib (EGFR) | The tumor grows again on CT (after 18–20 months on average) | C797S (10–15%); MET amplification (15–20%); SCLC transformation (3–5%) | Biopsy or ctDNA → platinum chemotherapy + pemetrexed ± continuation osimertinib |
| Alectinib (ALK) | Progression especially at the cerebral level | Secondary mutations in the ALK domain; MET amplification | Lorlatinib (generation III ) → covers and second-order ALK resistances |
| Sotorasib (KRAS G12C) | Progression after 6–8 months | KRAS G12C → G12D (10 – 15%); EGFR or MET amplification | Adagrasib (inhibitor exchange) or combination with chemotherapy |
| Pembrolizumab (immunotherapy) | Progression after variable PFS | Loss of PD-L1 expression; STK11 co-mutation occurred | Chemotherapy; rechallenge with another checkpoint inhibitor; clinical trials |
| Alpelisib (PIK3CA) | Progression after ~11 months | PTEN loss; emerging KRAS mutations; ERBB2 amplification | Everolimus + endocrine therapy; or chemotherapy |
| Olaparib (BRCA/PARP) | Progression after 2–3 years in ovarian | BRCA restoration (revertant mutations); ABCB1 amplification | Platinum chemotherapy (if > 6 months since last exposure); clinical trials |
| Trastuzumab (HER2) | CA 15-3 increases + imaging progression | PIK3CA amplification; loss of HER2 expression | T-DM1 or Trastuzumab deruxtecan (T-DXd); lapatinib or tucatinib |
📊 TABLE 7 — Test panels settled in Romania (PNCC 2025) — Practical guide
| Type of cancer | What tests are reimbursed? | What biomarkers do they detect? | Type of evidence required |
| Colorectal cancer (locally advanced or metastatic) | MSI/dMMR (IHC); RAS mutations (KRAS + NRAS exons 2,3,4); BRAF V600E; NTRK 1/2/3; PIK3CA; HER2 | MLH1, MSH2, MSH6, PMS2; KRAS G12C and other variants; BRAF; NTRK fusions | Paraffin block (tumor tissue) |
| ovarian cancer stages III–IV | BRCA1/2 somatic (Panel 1); BRCA1/2 germline (Panel 2 if Panel 1 inconclusive); HRD-GIS (Panel 3 if BRCA negative); NTRK | 52 genes included (BRCA1, BRCA2, ATM, CHEK2, PALB2, PTEN, RAD51C/D, TP53, etc.) | Paraffin block (Panel 1 and 3); Blood/saliva (Panel 2) |
| Non-squamous NSCLC lung cancer , metastatic | Complete NGS Panel (Com.Pl.it DX Long); PD-L1 | EGFR, BRAF V600E, KRAS G12C, ALK, ROS-1, NTRK, RET, STK11, KEAP1, MET, ERBB2 + 50 other genes; PD-L1 (clones 22C3, SP263, SP142) | Paraffin block; PD-L1 on tissue |
| NSCLC lung cancer , smokers, metastatic | PD-L1 IHC | PD-L1 (clones 22C3 IVD, SP263 IVD) | Paraffin block |
| Lung cancer operable stages | EGFR, ALK, PD-L1 | EGFR exons 18–21; ALK expression; PD-L1 (clone SP263) | Paraffin block |
| Breast cancer (all patients) | HR (ER/PR) + HER2 + Ki-67 | Estrogen receptors, progesteroneIci; HER2 IHC; Ki-67 | Paraffin block |
| HER2-negative, advanced/metastatic breast cancer | BRCA1/2 germline; NTRK; PIK3CA; PD-L1 | 52 gene panel; NTRK fusions; PIK3CA hotspot mutations; PD-L1 (clones 22C3 + SP142) | Paraffin block + blood/saliva |
| breast cancer , early stage high risk | BRCA1/2 germline | 52 genes hereditary panel | Blood or saliva |
| Squamous or adenosquamous esophageal cancer , advanced | PD-L1 | PD-L1 (clones 22C3 + 28-8) | Paraffin block |
| Esophageal adenocarcinoma , advanced | PD-L1 + HER2 | PD-L1 (clones 28-8); HER2 IHC ± FISH | Paraffin block |
| Gastric/gastroesophageal junction cancer , advanced | PD-L1 + HER2 | PD-L1 (clones 22C3 + 28-8); HER2 IHC ± FISH | Paraffin block |
| Locally advanced or metastatic urothelial cancer | PD-L1 | PD-L1 (clones 22C3 or 28-8) | Paraffin block |
| Recurrent/metastatic cervical cancer | PD-L1 | PD-L1 (clone 22C3) | Paraffin block |
📊 TABLE 8 — Molecular Results Traffic Light — Quick Visual Guide for Patients
| 🟢 GREEN — There is an approved targeted therapy | 🟡 YELLOW — Limited options or clinical trials available | 🔴 RED — No specific therapy, standard chemotherapy |
| Classic mutant EGFR (exon 19 del / L858R) → Osimertinib | EGFR exon 20 insertion → Amivantamab (less effective than classic TKIs) | KRAS non-G12C (G12D, G12V, etc.) → Chemotherapy |
| ALK positive → Alectinib / Lorlatinib | KRAS G12C (colorectal) → Sotorasib + chemotherapy ( in evaluation) | mutant TP53 → No direct therapy ; intensified chemotherapy |
| RET fusion → Selpercatinib | STK11 mutant → Chemotherapy; SHP2 inhibitors (studies) | NFE2L2/KEAP1 mutant → Standard chemotherapy |
| NTRK fusion → Larotrectinib (any cancer!) | PTEN loss → Everolimus/alpelisib ( in some cancers; partially approved ) | FBXW7 mutant → mTOR inhibitors (partial ) ; chemotherapy |
| BRAF V600E → Dabrafenib + Trametinib | PIK3CA mutant (other than breast cancer HR+) → Clinical trials | EP300 / ELF3 / HLA-B mutant → No specific approved therapy ; chemotherapy |
| BRCA1/2 mutant → Olaparib / Niraparib | Mutated TP53 + amplified MDM2 → MDM2 inhibitors (studies) | Isolated mutant MAPK1 → MEK inhibitors (studies in non-BRAF melanoma) |
| MSI-H / dMMR → Pembrolizumab (any cancer!) | Increased TMB 6–10 mut/Mb → Immunotherapy (variable benefit) | KRAS non-G12C + PD-L1 negative + low TMB → Chemotherapy only |
| PD-L1 ≥ 50% (pulmonary) → Pembrolizumab monotherapy | ERBB2 mutant (pulmonary, non-amplified) → Trastuzumab deruxtecan ( under evaluation) | STK11 + KRAS co-mutated → Preferred chemotherapy vs. immunotherapy |
| HER2 amplified (breast, gastric) → Trastuzumab + Pertuzumab | Mutant CBFB (AML leukemia) → Induction chemotherapy + bone marrow transplant | TP53 + RB1 lost → Intensive chemotherapy |
| KRAS G12C (pulmonary) → Sotorasib / Adagrasib | HER2-low (IHC 1+/2+) → Trastuzumab deruxtecan (T-DXd) — approved 2025 | PIK3CA in pancreatic cancer → There is no approved specific PI3K therapy |
💡 TABLE 9 — Essential questions to ask the doctor during the consultation (patient checklist)
| If you received this result | Mandatory questions for the oncologist |
| Diagnosed NSCLC lung cancer | “Was a full NGS panel recommended? Are EGFR, ALK, ROS1, RET, NTRK, BRAF V600E, KRAS G12C, PD-L1 tested? Is it reimbursed by PNCC?” |
| EGFR positive | “What exon is mutated? Exon 19 deletion or L858R? Can I get osimertinib as first line? Is it cleared?” |
| ALK/ROS1/RET positive | “What specific inhibitor is recommended? Is alectinib (ALK) or selpercatinib (RET) available in Romania at a discounted rate?” |
| KRAS G12C positive | “Am I eligible for sotorasib or adagrasib? Are there clinical trials with combinations?” |
| PD-L1 result received | “What is the exact score (TPS or CPS)? Can I receive pembrolizumab alone or combined with chemotherapy?” |
| STK11 mutant + PD-L1 elevated | “Given that I have mutant STK11, is chemotherapy more effective than immunotherapy alone?” |
| BRCA1/2 positive (ovarian/breast) | “Am I eligible for olaparib or niraparib as maintenance therapy? Is it covered by the PNCC?” |
| MSI-H/dMMR positive | “Can I receive pembrolizumab? If so, in what combination and from which line of treatment?” |
| HER2 IHC 2+ | “Has the FISH test been performed to clarify whether it is amplified or not? If FISH negative (HER2-low), am I eligible for trastuzumab deruxtecan?” |
| PIK3CA mutant (HR+ breast) | “Am I eligible for alpelisib + fulvestrant? Has basal blood glucose been tested (mandatory before alpelisib)?” |
| Mutated TP53 | “Are there clinical trials of APR-246 or MDM2 inhibitors for my type of cancer?” |
| Any rare mutation | “Are there ACTIVE clinical trials in Romania or Europe for my specific mutation? Does the clinicaltrials.gov website mention anything for my profile?” |
Disclaimer: The information in these tables is for informational and educational purposes only. It does not constitute a medical diagnosis, does not replace the consultation of a specialist physician, and does not represent a personalized therapeutic recommendation. Drug availability, settlement criteria, and therapeutic protocols are subject to change. Always consult your oncologist before making any medical decisions.
What does Oncoexpertai do with this information?
Receiving a genetic mutation report is often overwhelming. Terms like “EGFR exon 19 deletion,” “KRAS G12C wild-type,” or “PD-L1 TPS 45%” can be difficult to place in a clear therapeutic context.
Oncoexpertai.com platform automatically correlates your molecular profile with the latest NCCN, ESMO and EMA 2025 guidelines and generates a structured preliminary analysis. Our Artificial Intelligence algorithms can identify:
- What targeted therapies are you eligible to receive based on the mutations identified?
- Whether the current proposed scheme is aligned with international standards
- What biomarkers are missing from your file for a complete oncological decision
Technology does not replace the oncologist — it gives you the certainty that you arrive at the consultation with a complete file and the right questions .
Disclaimer: The information in this article is for informational and educational purposes only. It does not constitute a medical diagnosis, does not replace a specialist doctor’s consultation, and does not represent a personalized therapeutic recommendation. Any medical decision should be made exclusively after consultation with a qualified doctor, based on a complete assessment of your health condition. The reference values, therapeutic protocols, and medications mentioned may vary depending on the stage of the disease, the patient’s comorbidities, and the availability of medications in Romania — always consult your oncologist.
Bibliography
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 2025. NCCN; 2025.
- European Society for Medical Oncology. ESMO Clinical Practice Guidelines: Metastatic Non-Small-Cell Lung Cancer. Annals of Oncology. ESMO; actualizări 2023–2025.
- Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2018;29 Suppl 4:iv192–iv237.
- Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2018;378:113–125.
- Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. New England Journal of Medicine. 2020;382:41–50.
- Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer. New England Journal of Medicine. 2017;376:629–640.
- Skoulidis F, Li BT, Dy GK, et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. New England Journal of Medicine. 2021;384:2371–2381.
- Jänne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation. New England Journal of Medicine. 2022;387:120–131.
- Peters S, Camidge DR, Shaw AT, et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2017;377:829–838.
- Shaw AT, Ou SHI, Bang YJ, et al. Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2014;371:1963–1971.
- Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2020;383:813–824.
- Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children. New England Journal of Medicine. 2018;378:731–739.
- Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours and ROS1-positive non-small-cell lung cancer. Lancet Oncology. 2020;21(2):271–282.
- Planchard D, Besse B, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously treated BRAF V600E-mutant metastatic non-small cell lung cancer. Lancet Oncology. 2016;17(7):984–993.
- Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2016;375:1823–1833.
- Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2018;378:2078–2092.
- Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2018;379:2040–2051.
- Skoulidis F, Goldberg ME, Greenawalt DM, et al. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discovery. 2018;8(7):822–835.
- Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–413.
- André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer. New England Journal of Medicine. 2019;380:1929–1940.
- Robson M, Im SA, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. New England Journal of Medicine. 2017;377:523–533.
- Moore K, Colombo N, Scambia G, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. New England Journal of Medicine. 2018;379:2495–2505.
- Modi S, Saura C, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. New England Journal of Medicine. 2020;382:610–621.
- Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. New England Journal of Medicine. 2022;387:9–20.
- Food and Drug Administration. FDA Oncology Drug Approvals and Safety Communications. Silver Spring, MD: U.S. Food and Drug Administration; 2021–2025.
- European Medicines Agency. European Public Assessment Reports: Tagrisso, Keytruda, Lumykras, Enhertu, Retevmo, Vitrakvi, Rozlytrek. Amsterdam: EMA; 2021–2025.
- Ministerul Sănătății. Planul Național de Combatere și Control al Cancerului în România. București: Ministerul Sănătății; 2022–2025.
- Casa Națională de Asigurări de Sănătate. Programul Național de Oncologie: servicii medicale, medicamente și testări decontate. București: CNAS; 2024–2025.
- World Health Organization. WHO Classification of Tumours: Thoracic Tumours. 5th ed. Lyon: International Agency for Research on Cancer; 2021.
- Lindeman NI, Cagle PT, Aisner DL, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology. 2018;13(3):323–358.
Dr. Onisim Florin Senior Medical Oncologist | Founder of OncoExpertAI
.